NYMXF.US Nymox Pharmaceutical Corporation

Healthcare Biotechnology USA Stocks
0.0350 USD
Close of Nov 17, 2026
0.0002 0.1999
Market cap
USD 3.68M
P/E
-
P/B
44.60x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NYMXF.US undervalued?

Graham number

The Graham number of Nymox Pharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nymox Pharmaceutical Corporation fundamental analysis

No fundamental analysis for Nymox Pharmaceutical Corporation yet.

Nymox Pharmaceutical Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke …

Full company profile